Last year, the Trump administration proposed a rule that would have forced the middlemen to share more of their drug discounts with patients. Unfortunately, the administration caved to pressure from PBM lobbyists and shelved the proposal.

The actuarial firm Milliman estimated the cost-saving benefits for Medicare Part D under the Trump plan could save nearly $60 billion in drug costs up to 2029 and the taxpayers could save almost $100 billion.

By reintroducing his rebate rule, President Trump could lower drug prices by excluding middlemen who gobble up much of the price-discount savings. And he could tell voters “another promise kept.”

Merrill Matthews is a resident scholar with the Institute for Policy Innovation in Dallas, TX. Travel Advice-Don’t Forget the Toilet Paper